川宁生物：10月24日召开董事会会议

Core Viewpoint - Chuaning Bio announced the convening of its second board meeting to review the Q3 2025 report, indicating ongoing corporate governance and financial oversight [1] Company Overview - Chuaning Bio's revenue composition for the year 2024 is as follows: 93.72% from pharmaceutical manufacturing and 6.28% from other businesses [1] - As of the report, Chuaning Bio has a market capitalization of 24.8 billion yuan [1]